Investors purchased shares of Humana Inc (NYSE:HUM) on weakness during trading on Thursday. $75.01 million flowed into the stock on the tick-up and $52.87 million flowed out of the stock on the tick-down, for a money net flow of $22.14 million into the stock. Of all equities tracked, Humana had the 33rd highest net in-flow for the day. Humana traded down ($1.23) for the day and closed at $275.02
Several analysts recently weighed in on the stock. Zacks Investment Research reiterated a “hold” rating and issued a $306.00 price target on shares of Humana in a report on Monday, December 31st. Barclays reiterated a “buy” rating and issued a $351.00 price target on shares of Humana in a report on Sunday. Cowen assumed coverage on shares of Humana in a report on Monday, September 17th. They issued a “market perform” rating and a $372.00 price target on the stock. Cantor Fitzgerald reiterated a “hold” rating and issued a $325.00 price target on shares of Humana in a report on Wednesday, January 2nd. Finally, Credit Suisse Group lifted their price target on shares of Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a report on Thursday, November 8th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $354.63.
The firm has a market cap of $37.95 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 1.08 and a beta of 1.09. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45.
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend is Friday, December 28th. Humana’s dividend payout ratio (DPR) is presently 8.54%.
In other news, Director David A. Jr/Ky Jones sold 200 shares of Humana stock in a transaction dated Saturday, May 18th. The stock was sold at an average price of $230.04, for a total value of $46,008.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the transaction, the insider now directly owns 10,621 shares of the company’s stock, valued at approximately $3,622,398.26. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,078 shares of company stock worth $2,570,350. Company insiders own 0.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Moody National Bank Trust Division purchased a new position in shares of Humana in the 4th quarter worth about $30,000. Matthew Goff Investment Advisor LLC purchased a new position in shares of Humana in the 3rd quarter worth about $64,000. IMS Capital Management purchased a new position in shares of Humana in the 3rd quarter worth about $68,000. Stratos Wealth Partners LTD. purchased a new position in shares of Humana in the 3rd quarter worth about $108,000. Finally, Honkamp Krueger Financial Services Inc. purchased a new position in shares of Humana in the 3rd quarter worth about $108,000. 92.69% of the stock is owned by hedge funds and other institutional investors.
Humana Company Profile (NYSE:HUM)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Further Reading: Tariff
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.